GCP
IOVA icon

GSA Capital Partners’s Iovance Biotherapeutics IOVA Stock Holding History

GSA Capital Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.73M Buy
655,318
+98,233
+18% +$373K 0.17% 83
2026
Q1 		$1.96M Sell
557,085
-315,900
-36% -$1.01M 0.12% 180
2025
Q4 		$2.38M Buy
872,985
+793,763
+1,002% +$1.84M 0.21% 45
2025
Q3 		$172K Sell
79,222
-117,385
-60% -$277K 0.01% 1462
2025
Q2 		$338K Buy
196,607
+170,680
+658% +$425K 0.02% 1185
2025
Q1 		$86K Buy
+25,927
New +$134K 0.01% 1517
2024
Q4 		– Sell
-25,824
Closed -$242K – 1803
2024
Q3 		$242K Buy
+25,824
New +$245K 0.02% 1334
2024
Q2 		– Sell
-61,225
Closed -$907K – 1825
2024
Q1 		$907K Buy
+61,225
New +$713K 0.07% 502
2023
Q2 		– Sell
-216,782
Closed -$1.32M – 1716
2023
Q1 		$1.32M Buy
216,782
+40,989
+23% +$283K 0.13% 188
2022
Q4 		$1.12M Buy
175,793
+95,017
+118% +$742K 0.14% 165
2022
Q3 		$774K Sell
80,776
-97,802
-55% -$1.13M 0.1% 284
2022
Q2 		$1.97M Buy
178,578
+161,755
+962% +$2.12M 0.3% 13
2022
Q1 		$280K Buy
16,823
+1,425
+9% +$22K 0.04% 944
2021
Q4 		$294K Buy
+15,398
New +$339K 0.04% 946
2021
Q1 		– Sell
-5,321
Closed -$247K – 1282
2020
Q4 		$247K Buy
+5,321
New +$211K 0.04% 853
2019
Q2 		– Sell
-14,266
Closed -$136K – 1576
2019
Q1 		$136K Sell
14,266
-12,734
-47% -$124K 0.01% 1298
2018
Q4 		$239K Buy
+27,000
New +$260K 0.03% 989

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GSA Capital Partners's IOVA Position: Q2 2026 in Review

GSA Capital Partners increased its Iovance Biotherapeutics (IOVA) stake by 18% in Q2 2026, buying an estimated $373K and bringing the position to 655,318 shares worth $2.73M. The position accounts for 0.17% of the portfolio, ranked #83.

GSA Capital Partners first reported a position in IOVA in Q4 2018 and has held it in 17 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • GSA Capital Partners held 655,318 shares of Iovance Biotherapeutics worth $2.73M as of Q2 2026.
  • GSA Capital Partners bought 98,233 Iovance Biotherapeutics shares in Q2 2026, an estimated $373K.
  • Iovance Biotherapeutics made up 0.17% of GSA Capital Partners's portfolio in Q2 2026, its #83 holding.
  • GSA Capital Partners first reported a position in Iovance Biotherapeutics in Q4 2018 and has held it in 17 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.